Synlogic

Synlogic, Inc. (NASDAQ: SYBX) is a clinical-stage biopharmaceutical company applying synthetic biology principles to the engineering of probiotic bacteria — using genetic engineering tools to program gut bacteria to perform specific therapeutic functions within the human gastrointestinal tract. According to its website at synlogictx.com, Synlogic's Synthetic Biotic medicine platform engineers strains of Lactobacillus and E. coli Nissle 1917 — gut bacteria with established safety profiles as dietary supplements and probiotics — to produce specific therapeutic molecules, consume specific harmful metabolites, or activate specific immune pathways at the site of gastrointestinal disease, providing localized therapeutic action without the systemic drug exposure and toxicity concerns of conventional pharmaceuticals. The platform's potential applications span metabolic diseases, inflammatory bowel disease, liver diseases, and cancer immunotherapy.

Synlogic's clinical development pipeline, described at synlogictx.com, has advanced engineered Synthetic Biotic strains through multiple clinical programs, including SYNB1618 and SYNB1934 for phenylketonuria (PKU) — a rare metabolic disorder caused by the inability to metabolize the amino acid phenylalanine, leading to neurotoxic accumulation — where engineered bacteria that consume intestinal phenylalanine could provide therapeutic benefit by reducing systemic phenylalanine levels. The company has also developed SYNB8802 for enteric hyperoxaluria — a condition characterized by excessive intestinal oxalate absorption that causes kidney stones and kidney failure — where bacteria engineered to degrade intestinal oxalate could reduce its absorption and prevent the renal complications of hyperoxaluria. These programs represent first-in-class approaches to metabolic disease management using engineered probiotic bacteria as living medicines.

Synlogic has also explored the application of its Synthetic Biotic platform to cancer immunotherapy — developing engineered bacteria designed to colonize the tumor microenvironment and produce immunostimulatory molecules that activate anti-tumor immune responses at the tumor site with minimal systemic exposure. According to synlogictx.com, the company's synthetic biology platform represents a potentially transformative approach to drug development that could address disease indications where conventional pharmaceuticals face significant efficacy, safety, or delivery challenges. Synlogic's combination of synthetic biology drug development platform, metabolic disease clinical programs, cancer immunotherapy application, clinical-stage development status, and Nasdaq-listed public company structure reflects its pioneering position at the intersection of biotechnology and synthetic biology in the emerging field of engineered living medicines.